DiogenX Funding: How Much Did They Raise & Key Investors

How Much Did DiogenX Raise?
Funding & Key Investors

DiogenX, a preclinical stage biotechnology firm, has successfully secured a major strategic investment, bringing its total capital raised to $30.3M. This latest financing round, totaling $30.3M, underscores the market confidence in the company's proprietary approach to addressing beta-cell failure. By focusing on the functional recovery of beta-cells, DiogenX is positioning itself at the forefront of metabolic disease research, attracting significant interest from both venture impact funds and global pharmaceutical leaders.

The infusion of capital marks a pivotal moment for the organization as it transitions from laboratory-based discovery to more advanced development phases. With this backing, the company is well-equipped to accelerate its lead program, which aims to rebalance glucose and insulin homeostasis for millions of patients worldwide.

What is DiogenX?

DiogenX

Business Services

Research & Development

DiogenX is a specialized biotechnology company dedicated to the discovery and development of innovative biologics for the treatment of diabetes. Originating from the research of Dr. Patrick Collombat, the company's core technology targets the underlying mechanisms of beta-cell failure. Unlike traditional treatments that primarily manage symptoms, DiogenX focuses on regenerative therapeutic options that stimulate functional recovery. This unique mode of action represents a significant shift in the diabetes treatment landscape, offering the potential for clinically meaningful improvements in patient outcomes and long-term disease management.

How much funding has DiogenX raised?

DiogenX has raised a total of $30.3M across 1 funding round:

2023

Series A

$30.3M

Series A (2023): $30.3M with participation from Omnes Capital, JDRF T1D Fund, Eli Lilly and Company Pvt, and Boehringer Ingelheim Venture Fund

Key Investors in DiogenX

Omnes Capital

A leading European private equity firm focused on the energy transition and deeptech innovation, managing over 6.7 billion euros in assets.

JDRF T1D Fund

A specialized venture impact fund dedicated to accelerating treatments and cures for Type 1 Diabetes with over 200 million dollars in assets under management.

Eli Lilly and Company Pvt

A subsidiary of the global biopharmaceutical giant, specializing in advanced treatment options for chronic diseases including diabetes and oncology.

What's next for DiogenX?

With the recent influx of capital, DiogenX is poised to scale its preclinical operations and advance its lead therapeutic candidate toward clinical trials. The strategic involvement of major pharmaceutical and venture partners suggests a clear roadmap for regulatory engagement and potential future partnerships. As the company continues to refine its biologics platform, the focus will remain on validating the efficacy of its beta-cell recovery approach in human models. This phase is critical for establishing the company as a leader in the next generation of metabolic therapeutics, potentially setting a new standard for care in the global diabetes market.

See full DiogenX company page

See More Financial Insights